Skip to main navigation
Skip to search
Skip to main content
University of Luebeck Home
English
Deutsch
Home
Research Units
Experts
Publications
Projects
Datasets
Prizes
Spin-Offs
Activities
Media
Search by expertise, name or affiliation
Immuncheckpointinhibition beim Merkel-Zell-Karzinom
Translated title of the contribution
:
Immune checkpoint inhibition in Merkel cell carcinoma
P. Terheyden
*
, A. Mohr,
E. A. Langan
*
Corresponding author for this work
Clinic of Dermatology, Allergology and Venerology
1
Citation (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Immune checkpoint inhibition in Merkel cell carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Immunity
100%
Merkel Cell Carcinoma
100%
Avelumab
28%
Survival Rate
28%
Neoplasm
14%
Metastatic Carcinoma
14%
Tumor Biology
14%
Treatment Response
14%
Contraindication
14%
Programmed Cell Death
14%
Skin Cancer
14%
Pembrolizumab
14%
Immune Checkpoint Inhibitor
14%
Blocking Antibody
14%
Programmed Death 1 Receptor
14%
Merkel cell polyomavirus
14%
Pharmacology, Toxicology and Pharmaceutical Science
Merkel Cell Carcinoma
100%
Neoplasm
28%
Survival Rate
28%
Metastasis
14%
Long Term Exposure
14%
Immune Checkpoint Inhibitor
14%
Programmed Cell Death
14%
Blocking Antibody
14%
Pembrolizumab
14%
Programmed Death 1 Receptor
14%